Dashboard
1
Poor Management Efficiency with a low ROCE of 0%
- The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward
2
High Debt Company with a Debt to Equity ratio (avg) at times
3
Poor long term growth as Net Sales has grown by an annual rate of -1.08% and Operating profit at 14.40% over the last 5 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 3,264 Million (Small Cap)
33.00
NA
0.00%
-0.54
12.02%
2.91
Revenue and Profits:
Net Sales:
76 Million
(Quarterly Results - Sep 2025)
Net Profit:
-8 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
88.89%
0%
88.89%
6 Months
59.64%
0%
59.64%
1 Year
132.96%
0%
132.96%
2 Years
54.55%
0%
54.55%
3 Years
20.27%
0%
20.27%
4 Years
42.95%
0%
42.95%
5 Years
32.7%
0%
32.7%
Zhejiang Yatai Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-1.08%
EBIT Growth (5y)
14.40%
EBIT to Interest (avg)
-1.50
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.46
Sales to Capital Employed (avg)
0.32
Tax Ratio
1.54%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
1.39%
Valuation key factors
Factor
Value
P/E Ratio
33
Industry P/E
Price to Book Value
3.74
EV to EBIT
-107.51
EV to EBITDA
2727.58
EV to Capital Employed
6.76
EV to Sales
11.04
PEG Ratio
0.05
Dividend Yield
NA
ROCE (Latest)
-6.29%
ROE (Latest)
11.39%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
76.20
87.50
-12.91%
Operating Profit (PBDIT) excl Other Income
-10.80
-1.80
-500.00%
Interest
0.00
32.20
-100.00%
Exceptional Items
-1.40
2.40
-158.33%
Consolidate Net Profit
-8.00
113.00
-107.08%
Operating Profit Margin (Excl OI)
-141.30%
-119.40%
-2.19%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is -12.91% vs 35.45% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is -107.08% vs 1,548.72% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
403.20
418.90
-3.75%
Operating Profit (PBDIT) excl Other Income
27.40
8.30
230.12%
Interest
30.60
47.50
-35.58%
Exceptional Items
-3.30
49.00
-106.73%
Consolidate Net Profit
34.20
-11.90
387.39%
Operating Profit Margin (Excl OI)
-24.00%
-76.60%
5.26%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -3.75% vs 12.52% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 387.39% vs 91.03% in Dec 2023
About Zhejiang Yatai Pharmaceutical Co., Ltd. 
Zhejiang Yatai Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






